103 related articles for article (PubMed ID: 17452300)
1. The past, presence and future of ADMA in nephrology.
Kielstein JT; Fliser D
Nephrol Ther; 2007 Apr; 3(2):47-54. PubMed ID: 17452300
[TBL] [Abstract][Full Text] [Related]
2. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?
Kielstein JT; Zoccali C
Am J Kidney Dis; 2005 Aug; 46(2):186-202. PubMed ID: 16112037
[TBL] [Abstract][Full Text] [Related]
3. Asymmetric dimethylarginine and symmetric dimethylarginine: axis of evil or useful alliance?
Kielstein JT; Fliser D; Veldink H
Semin Dial; 2009; 22(4):346-50. PubMed ID: 19708979
[TBL] [Abstract][Full Text] [Related]
4. Dimethylarginines ADMA and SDMA: the real water-soluble small toxins?
Schepers E; Speer T; Bode-Böger SM; Fliser D; Kielstein JT
Semin Nephrol; 2014 Mar; 34(2):97-105. PubMed ID: 24780466
[TBL] [Abstract][Full Text] [Related]
5. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease.
Ueda S; Yamagishi SI; Matsumoto Y; Fukami K; Okuda S
Clin Exp Nephrol; 2007 Jun; 11(2):115-121. PubMed ID: 17593510
[TBL] [Abstract][Full Text] [Related]
6. Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease.
Kielstein JT; Zoccali C
Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):609-15. PubMed ID: 18941355
[TBL] [Abstract][Full Text] [Related]
7. Symmetrical dimethylarginine predicts mortality in the general population: observations from the Dallas heart study.
Gore MO; Lüneburg N; Schwedhelm E; Ayers CR; Anderssohn M; Khera A; Atzler D; de Lemos JA; Grant PJ; McGuire DK; Böger RH
Arterioscler Thromb Vasc Biol; 2013 Nov; 33(11):2682-8. PubMed ID: 24008162
[TBL] [Abstract][Full Text] [Related]
8. Level of asymmetric dimethylarginine and carotid atherosclerosis in patients with chronic kidney disease.
Zhang WR; Hou FF; Ning JP; Yang XB; Wu Q; Tao LJ; Chen BM; Li HY; Chang L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):621-8. PubMed ID: 17062918
[TBL] [Abstract][Full Text] [Related]
9. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
Böger RH; Bode-Böger SM
Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410
[TBL] [Abstract][Full Text] [Related]
10. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
Busch M; Fleck C; Wolf G; Stein G
Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
[TBL] [Abstract][Full Text] [Related]
11. Association of asymmetric dimethylarginine and endothelial dysfunction.
Böger RH
Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
[TBL] [Abstract][Full Text] [Related]
12. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
Siroká R; Cibulka R; Rajdl D; Racek J
Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
[TBL] [Abstract][Full Text] [Related]
13. Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients.
Kumagai H; Sakurai M; Takita T; Maruyama Y; Uno S; Ikegaya N; Kato A; Hishida A
Am J Kidney Dis; 2006 Nov; 48(5):797-805. PubMed ID: 17059999
[TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism.
Wilcken DE; Sim AS; Wang J; Wang XL
Mol Genet Metab; 2007 Aug; 91(4):309-17; discussion 308. PubMed ID: 17560156
[TBL] [Abstract][Full Text] [Related]
15. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure.
Nanayakkara PW; Teerlink T; Stehouwer CD; Allajar D; Spijkerman A; Schalkwijk C; ter Wee PM; van Guldener C
Kidney Int; 2005 Nov; 68(5):2230-6. PubMed ID: 16221223
[TBL] [Abstract][Full Text] [Related]
16. Circulating angiopoietin-2 levels increase with progress of chronic kidney disease.
David S; Kümpers P; Lukasz A; Fliser D; Martens-Lobenhoffer J; Bode-Böger SM; Kliem V; Haller H; Kielstein JT
Nephrol Dial Transplant; 2010 Aug; 25(8):2571-6. PubMed ID: 20179005
[TBL] [Abstract][Full Text] [Related]
17. Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move.
Zoccali C
J Hypertens; 2006 Apr; 24(4):611-9. PubMed ID: 16531785
[TBL] [Abstract][Full Text] [Related]
18. [Asymmetric dimethylarginine: metabolism, arginine paradox, pathophysiology].
Gilinskiĭ MA
Usp Fiziol Nauk; 2007; 38(3):21-39. PubMed ID: 17977229
[TBL] [Abstract][Full Text] [Related]
19. Association of Circulating Levels of ADMA with Carotid Intima-Media Thickness in Patients with CKD: a Systematic Review and Meta-Analysis.
Wang F; Xiong R; Feng S; Lu X; Li H; Wang S
Kidney Blood Press Res; 2018; 43(1):25-33. PubMed ID: 29393214
[TBL] [Abstract][Full Text] [Related]
20. Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease.
Zoccali C
Blood Purif; 2002; 20(5):469-72. PubMed ID: 12207095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
